Biotech News

Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics (ATXI)Avenue Therapeutics2026-06-25 13:46 ESTEarnings

ATXI (ATXI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is atxi.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

ATXIAvenue Therapeutics2026-06-25 13:46 EST

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

ATXIAvenue Therapeutics2026-06-25 13:46 EST

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

ATXIAvenue Therapeutics2026-06-25 13:46 EST

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

ATXIAvenue Therapeutics2026-06-25 13:46 EST

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

ATXIAvenue Therapeutics2026-06-25 13:46 EST

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

ATXIAvenue Therapeutics2026-06-25 13:46 EST

Avenue Therapeutics to Participate in Upcoming Investor Conferences

ATXIAvenue Therapeutics2026-06-25 13:46 EST

Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

ATXIAvenue Therapeutics2026-06-25 13:46 EST

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

ATXIAvenue Therapeutics2026-06-25 13:46 EST

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

Avenue Therapeutics

Avenue Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ATXIAvenue Therapeutics2026-06-26 12:06 EST

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

ATXIAvenue Therapeutics2026-06-26 12:06 EST

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

ATXIAvenue Therapeutics2026-06-26 12:06 EST

Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

ATXIAvenue Therapeutics2026-06-26 12:06 EST

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

ATXIAvenue Therapeutics2026-06-26 12:06 EST

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States